secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gritstone bio, Inc. (—)
CIK:        0001656634
Form:       8-K
Filed at:   2025-01-03T23:59:59+00:00
Accession:  0001193125-25-001488
Event type: m_and_a
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 2.01, 1.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gritstone bio sells assets for $21.25M to Seattle Project Corp. in Ch11; CEO and top officers resign
--------------------------------------------------------------------------------

- Sold substantially all assets (excl. machinery, Binder IP) to Seattle Project Corp. for $21.25M cash at closing.
- Effective Dec 31, 2024: CEO Andrew Allen, CBO Matthew Hawryluk, COO Erin Jones, R&D head Karin Jooss resigned without cause.
- Celia Economides named interim CEO and CFO effective Dec 31, 2024; no change in compensation.
- Bankruptcy Court approved sale on Dec 23, 2024; closing occurred Dec 30, 2024.
- Company cautions that trading in common stock (GRTSQ) is highly speculative due to Chapter 11 Case.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1656634/000119312525001488/0001193125-25-001488-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1656634/000119312525001488/d905705d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-001488

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer